文献速递新发突发、热带与寄生虫病

不同佐剂PAMVAC预防妊娠相关疟疾的首次人体随机双盲临床试验

First-in-human, Randomized, Double-blind Clinical Trial of Differentially Adjuvanted PAMVAC, A Vaccine Candidate to Prevent Pregnancy-associated Malaria.
PubMed 文献 · Clin Infect Dis · 2019-01-01

该首次人体随机双盲试验将PAMVAC(基于VAR2CSA重组片段的候选疫苗)以20 μg或50 μg联合Alhydrogel、GLA-SE或GLA-LSQ佐剂,间隔4周肌注3剂免疫疟疾未暴露健康成人。所有制剂安全耐受,无严重不良事件,均具免疫原性,PAMVAC-GLA-SE诱导的抗体水平最高,且抗体可抑制VAR2CSA表达感染红细胞与CSA结合。

要点

  • PAMVAC所有佐剂制剂安全耐受,无严重不良事件。
  • PAMVAC-GLA-SE诱导的疫苗特异性抗体水平最高。
  • 抗体可抑制VAR2CSA表达感染红细胞与CSA结合。

核心结论

  • PAMVAC联合Alhydrogel或GLA类佐剂安全、耐受良好,并诱导具有功能活性的抗体。

研究设计与样本

  • 首次人体、随机、双盲临床试验。
  • 健康、成人、疟疾未暴露志愿者接受3次肌注,每次20 μg(n=9)或50 μg(n=27)PAMVAC。
  • 佐剂为Alhydrogel、GLA-SE或GLA-LSQ,每4周给药一次,末次免疫后观察6个月。

主要发现

  • 所有PAMVAC制剂安全且耐受良好,共发生262例不良事件(AEs),其中94例至少可能与疫苗相关(10例2级、2例3级)。
  • 无严重不良事件发生,各臂不良事件分布和严重程度相似。
  • PAMVAC在所有参与者中具有免疫原性,PAMVAC-GLA-SE诱导的PAMVAC特异性抗体水平最高。
  • 抗体在标准化功能试验中抑制VAR2CSA表达恶性疟原虫感染红细胞与CSA结合。

临床怎么用

  • 下一步将在疟疾流行区未初次妊娠妇女中评估PAMVAC。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Malaria in pregnancy has major impacts on mother and child health. To complement existing interventions, such as intermittent preventive treatment and use of impregnated bed nets, we developed a malaria vaccine candidate with the aim of reducing sequestration of asexual "blood-stage" parasites in the placenta, the major virulence mechanism. METHODS: The vaccine candidate PAMVAC is based on a recombinant fragment of VAR2CSA, the Plasmodium falciparum protein responsible for binding to the placenta via chondroitin sulfate A (CSA). Healthy, adult malaria-naive volunteers were immunized with 3 intramuscular injections of 20 μg (n = 9) or 50 μg (n = 27) PAMVAC, adjuvanted with Alhydrogel or glucopyranosyl lipid adjuvant in stable emulsion (GLA-SE) or in a liposomal formulation with QS21 (GLA-LSQ). Allocation was random and double blind. The vaccine was given every 4 weeks. Volunteers were observed for 6 months following last immunization. RESULTS: All PAMVAC formulations were safe and well tolerated. A total of 262 adverse events (AEs) occurred, 94 (10 grade 2 and 2 grade 3) at least possibly related to the vaccine. No serious AEs occurred. Distribution and severity of AEs were similar in all arms. PAMVAC was immunogenic in all participants. PAMVAC-specific antibody levels were highest with PAMVAC-GLA-SE. The antibodies inhibited binding of VAR2CSA expressing P. falciparum-infected erythrocytes to CSA in a standardized functional assay. CONCLUSIONS: PAMVAC formulated with Alhydrogel or GLA-based adjuvants was safe, well tolerated, and induced functionally active antibodies. Next, PAMVAC will be assessed in women before first pregnancies in an endemic area. CLINICAL TRIALS REGISTRATION: EudraCT 2015-001827-21; ClinicalTrials.gov NCT02647489.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Mordmüller B, Sulyok M, Egger-Adam D, et al. First-in-human, Randomized, Double-blind Clinical Trial of Differentially Adjuvanted PAMVAC, A Vaccine Candidate to Prevent Pregnancy-associated Malaria. Clin Infect Dis. 2019. PMID: 30629148. doi:10.1093/cid/ciy1140

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。